辐射暴露生物标志物的临床应用：局限性及通过协同研究可能的解决方案

CLINICAL APPLICATIONS OF BIOMARKERS OF RADIATION EXPOSURE: LIMITATIONS AND POSSIBLE SOLUTIONS THROUGH COORDINATED RESEARCH.

作者信息

Vinnikov Volodymyr, Belyakov Oleg

机构信息

Grigoriev Institute for Medical Radiology of the National Academy of Medical Science of Ukraine, Pushkinskaya St. 82, Kharkiv 61024, Ukraine.

The International Atomic Energy Agency, P.O. Box 100, Wagramerstrasse 5, Vienna, Austria.

出版信息

Radiat Prot Dosimetry. 2019 Dec 31;186(1):3-8. doi: 10.1093/rpd/ncz038.

DOI:10.1093/rpd/ncz038

PMID:30916766

Abstract

Dosimetric biomarkers have been effectively and intensively used for a long time in the area of radiation protection. In contrast to that, no robust standards or widely accepted protocols for application of these end-points in radiotherapy, diagnostic and interventional radiology and nuclear medicine exist to date. The International Atomic Energy Agency (IAEA) organized the review of the available data on the possibilities of the use of dosimetric biomarkers in medical irradiation scenarios. The resultant Technical Report also contains a summary of identified problems, gaps in knowledge, limitations in methodology and recommendations for their overcoming. This work provided a conceptual background for the initiation of a new IAEA Coordinated Research Project E35010, MEDBIODOSE (2017-21), which is aimed specifically at the development and improvement of applications of biodosimetric markers in clinical practice.

摘要

剂量生物标志物在辐射防护领域长期得到有效且广泛的应用。相比之下，目前在放射治疗、诊断和介入放射学以及核医学中，对于应用这些终点指标尚无稳健的标准或广泛认可的方案。国际原子能机构（IAEA）组织对在医学照射场景中使用剂量生物标志物的可能性的现有数据进行了审查。所得的技术报告还总结了已识别的问题、知识空白、方法学局限性以及克服这些问题的建议。这项工作为启动IAEA的一个新的协调研究项目E35010，即MEDBIODOSE（2017 - 2021年）提供了概念背景，该项目专门旨在开发和改进生物剂量标志物在临床实践中的应用。